Key facts
- This page summarizes Octavio Espinoza's Form 4 filing for LIGAND PHARMACEUTICALS INC (LGND).
- 11 reported transactions and 5 derivative rows are listed below.
- Accepted by SEC: 14 Aug 2026, 17:05.
Octavio Espinoza - 12 Aug 2026 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- LGND
- Reported as of
- 12 Aug 2026
- Net transaction value
- -$9,241,229
- SEC form
- 4
- Accepted by SEC
- 14 Aug 2026, 17:05:08 UTC
- Prior SEC filing
- 06 Jul 2026
- Source filing
- View source filing
- Reporting owner signature
- By: /s/ Andrew Reardon, Attorney-in-Fac For: Octavio Espinoza
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Octavio Espinoza filed Form 4 for LIGAND PHARMACEUTICALS INC (LGND) on 14 Aug 2026.
Change
- Previous filing in this sequence was filed on 06 Jul 2026.
- Current net transaction value: -$9,241,229.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001905248
Primary reporting owner
Espinoza Octavio
- Relationship
- Chief Financial Officer
- Address
- 555 HERITAGE DRIVE, SUITE 200, JUPITER
- Signature
- By: /s/ Andrew Reardon, Attorney-in-Fac For: Octavio Espinoza
- Signature date
- 13 Aug 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LGND
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +16,179
- Change %
- +58%
- Price
- $52.84*
- Shares after
- 43,875
- Date
- 12 Aug 2026
- Ownership
- Direct
- Footnotes
- F1
LGND
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +2,074
- Change %
- +4.7%
- Price
- $70.04*
- Shares after
- 45,949
- Date
- 12 Aug 2026
- Ownership
- Direct
- Footnotes
- F1
LGND
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +2,869
- Change %
- +6.2%
- Price
- $55.75*
- Shares after
- 48,818
- Date
- 12 Aug 2026
- Ownership
- Direct
- Footnotes
- F1
LGND
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +7,171
- Change %
- +15%
- Price
- $57.22*
- Shares after
- 55,989
- Date
- 12 Aug 2026
- Ownership
- Direct
- Footnotes
- F1
LGND
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +3,348
- Change %
- +6%
- Price
- $68.74*
- Shares after
- 59,337
- Date
- 12 Aug 2026
- Ownership
- Direct
- Footnotes
- F1
LGND
transaction
Common Stock
Sale
- Transaction value
- $9,241,229
- Shares
- -31,641
- Change %
- -53%
- Price
- $292.06
- Shares after
- 27,696
- Date
- 12 Aug 2026
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LGND
transaction
Derivative
Employee Stock Option (right to buy)
Options Exercise
- Transaction value
- Shares
- -2,869
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 12 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,869
- Exercise price
- $55.75
- Footnotes
- F1, F3
LGND
transaction
Derivative
Employee Stock Option (right to buy)
Options Exercise
- Transaction value
- Shares
- -7,171
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 12 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 7,171
- Exercise price
- $57.22
- Footnotes
- F1, F4
LGND
transaction
Derivative
Non-Qualified Stock Option (right to buy)
Options Exercise
- Transaction value
- Shares
- -16,179
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 12 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 16,179
- Exercise price
- $52.84
- Footnotes
- F1, F5
LGND
transaction
Derivative
Non-Qualified Stock Option (right to buy)
Options Exercise
- Transaction value
- Shares
- -3,348
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 12 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,348
- Exercise price
- $68.74
- Footnotes
- F1, F6
LGND
transaction
Derivative
Non-Qualified Stock Option (right to buy)
Options Exercise
- Transaction value
- Shares
- -2,074
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 12 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,074
- Exercise price
- $70.04
- Footnotes
- F1, F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 7 footnotes
Footnote F1
The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1.
Footnote F2
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $292.0098 to $292.0846. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F3
The original grant of 4,039 stock options vests and is exercisable as to approximately 15% of the underlying shares on August 13, 2020, approximately 70% of the underlying shares in 28 substantially equal monthly installments beginning on September 13, 2020, and approximately 15% of the underlying shares in 12 substantially equal monthly installments thereafter.
Footnote F4
The stock option vests and is exercisable as to approximately 14% of the underlying shares on April 1, 2021, approximately 73% of the underlying shares in 32 substantially equal monthly installments on May 5, 2021, and approximately 13% of the underlying shares in 10 substantially equal monthly installments thereafter.
Footnote F5
The stock option vests and is exercisable as to approximately 14% of the underlying shares on August 5, 2022, approximately 64% of the underlying shares in 28 substantially equal monthly installments beginning on September 5, 2022, and approximately 22% of the underlying shares in 12 substantially equal monthly installments thereafter.
Footnote F6
The stock option vests and is exercisable as to approximately 13% of the underlying shares on August 11, 2019, and the remaining of the underlying shares in 40 substantially equal monthly installments thereafter.
Footnote F7
The stock option vests and is exercisable as to approximately 16% of the underlying shares on August 1, 2019, approximately 74% of the underlying shares in 28 substantially equal monthly installments beginning on September 1, 2019, and approximately 10% of the underlying shares in 12 substantially equal monthly installments thereafter.